Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Q32 Bio (QTTB) has issued an announcement.
Q32 Bio Inc. has successfully completed the enrollment phase for the SIGNAL-AD Phase 2 clinical trial of their drug bempikibart, aimed at treating persistent, moderate-to-severe atopic dermatitis. The trial explores the efficacy of bempikibart, an antibody that blocks inflammatory signaling with the hope of re-regulating immune function. With 121 patients enrolled, surpassing the initial goal due to high demand, the study’s findings are eagerly anticipated in the fourth quarter of 2024. This milestone marks a significant step for Q32 Bio Inc. as they advance in the development of potential new treatments for autoimmune disorders.
For a thorough assessment of QTTB stock, go to TipRanks’ Stock Analysis page.
